C-DQ79Lift Biosciences
allogeneic neutrophils, cell therapy, immuno-oncology
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DQ79
C-DQ79C-DQ79allogeneic neutrophils, cell therapy, immuno-oncology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Lift Biosciences allogeneic neutrophils, cell therapy, immuno-oncology
LIFT BioSciences is developing allogeneic Immuno-Modulatory Alpha Neutrophils, or IMANs, for hard-to-treat cancers. Its platform uses neutrophils' tumour-homing, tumour-infiltrating and direct cancer-cell-killing attributes to re-ignite anti-tumour immunity. The company is advancing a pipeline across multiple solid cancers, with a first-in-human Phase 1 study planned for advanced cervical and head and neck cancers.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Lift Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic